×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:PETQ

PetIQ Stock Forecast, Price & News

$17.71
+0.92 (+5.48%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$16.68
$17.71
50-Day Range
$14.09
$21.57
52-Week Range
$13.56
$39.08
Volume
223,725 shs
Average Volume
262,940 shs
Market Capitalization
$520.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.25

PetIQ Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
76.5% Upside
$31.25 Price Target
Short Interest
Healthy
9.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$158.98 K Bought Last Quarter
Proj. Earnings Growth
44.87%
From $0.78 to $1.13 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.03 out of 5 stars

Medical Sector

453rd out of 1,428 stocks

Drugs, Proprietaries, & Sundries Industry

7th out of 8 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive PETQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PetIQ and its competitors with MarketBeat's FREE daily newsletter.

PetIQ logo

About PetIQ (NASDAQ:PETQ)

PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at 2,900 community clinics and wellness centers hosted at pet retailers across 42 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.

PETQ Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drugs, proprietaries, & sundries
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PETQ
Fax
N/A
Employees
1,929
Year Founded
N/A

Company Calendar

Last Earnings
5/04/2022
Today
7/03/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$31.25
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$29.00
Forecasted Upside/Downside
+76.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-15.97 million
Pretax Margin
-1.23%

Debt

Sales & Book Value

Annual Sales
$932.53 million
Cash Flow
$2.09 per share
Book Value
$8.68 per share

Miscellaneous

Free Float
26,848,000
Market Cap
$520.85 million
Optionable
Optionable
Beta
1.48














PetIQ Frequently Asked Questions

Should I buy or sell PetIQ stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PetIQ in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PetIQ stock.
View analyst ratings for PetIQ
or view top-rated stocks.

What is PetIQ's stock price forecast for 2022?

4 Wall Street analysts have issued 1-year price targets for PetIQ's shares. Their PETQ stock forecasts range from $29.00 to $36.00. On average, they predict PetIQ's stock price to reach $31.25 in the next year. This suggests a possible upside of 76.5% from the stock's current price.
View analysts' price targets for PetIQ
or view top-rated stocks among Wall Street analysts.

How has PetIQ's stock performed in 2022?

PetIQ's stock was trading at $22.71 on January 1st, 2022. Since then, PETQ shares have decreased by 22.0% and is now trading at $17.71.
View the best growth stocks for 2022 here
.

When is PetIQ's next earnings date?

PetIQ is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for PetIQ
.

How were PetIQ's earnings last quarter?

PetIQ, Inc. (NASDAQ:PETQ) posted its quarterly earnings data on Wednesday, May, 4th. The company reported $0.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.29 by $0.20. The company had revenue of $275.70 million for the quarter, compared to the consensus estimate of $269.45 million. PetIQ had a negative net margin of 1.56% and a positive trailing twelve-month return on equity of 10.92%. The business's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.31 earnings per share.
View PetIQ's earnings history
.

What guidance has PetIQ issued on next quarter's earnings?

PetIQ updated its second quarter 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $260.00 million-$271.00 million, compared to the consensus revenue estimate of $286.90 million.

Who are PetIQ's key executives?

PetIQ's management team includes the following people:

What is Cord Christensen's approval rating as PetIQ's CEO?

10 employees have rated PetIQ CEO Cord Christensen on Glassdoor.com. Cord Christensen has an approval rating of 89% among PetIQ's employees.

What other stocks do shareholders of PetIQ own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PetIQ investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Exelixis (EXEL), Intel (INTC), CVS Health (CVS), QUALCOMM (QCOM), Editas Medicine (EDIT) and Gilead Sciences (GILD).

When did PetIQ IPO?

(PETQ) raised $86 million in an initial public offering (IPO) on Friday, July 21st 2017. The company issued 5,700,000 shares at $14.00-$16.00 per share. Jefferies and William Blair served as the underwriters for the IPO and Oppenheimer, Raymond James and SunTrust Robinson Humphrey were co-managers.

What is PetIQ's stock symbol?

PetIQ trades on the NASDAQ under the ticker symbol "PETQ."

How do I buy shares of PetIQ?

Shares of PETQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PetIQ's stock price today?

One share of PETQ stock can currently be purchased for approximately $17.71.

How much money does PetIQ make?

PetIQ (NASDAQ:PETQ) has a market capitalization of $520.85 million and generates $932.53 million in revenue each year. The company earns $-15.97 million in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does PetIQ have?

PetIQ employs 1,929 workers across the globe.

How can I contact PetIQ?

PetIQ's mailing address is 923 S. Bridgeway Pl., EAGLE ID, 83616. The official website for PetIQ is www.petiq.com. The company can be reached via phone at (208) 939-8900 or via email at jeff.sonnek@icrinc.com.

This page (NASDAQ:PETQ) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.